Databases - ALZFORUM
WEBAlzAntibodies. This database aims to provide detailed descriptions of selected antibodies related to the study of Alzheimer’s disease. AlzBiomarker
ALZFORUM | NETWORKING FOR A CURE
WEB3 days ago — Andrea Pfeifer on A Country Doctor, But Oh So Much More: Francisco Lopera, 73 01 Oct 2024; Marc Aurel Busche on Synaptic Skirmish: Aβ and Tau Pathologies Battle Over Brain Rhythms 01 Oct 2024; Michael Belloy on X-Chromosome-Wide Association Data Spot Alzheimer’s Loci 30 Sep 2024; Evan Macosko and Vishal Sarsani on Glial Cell Communities Conspire to Drive Alzheimer’s Disease 26 Sep 2024
Donepezil - ALZFORUM
WEBMay 16, 2023 — Overview. Name: Donepezil Synonyms: Aricept™, Donepezil hydrochloride, Eranz®, E 2020 Chemical Name: 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one Therapy Type: Small Molecule Target Type: Cholinergic System Condition(s): Alzheimer's Disease, Dementia with Lewy Bodies, Down's Syndrome, Parkinson's Disease Dementia U.S. FDA Status: Alzheimer's Disease (Approved ...
Donanemab | ALZFORUM
WEBFeb 14, 2019 — Overview. Name: Donanemab Synonyms: N3pG-Aβ Monoclonal Antibody, LY3002813, Kisunla Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: Eli Lilly & Co. Background. Donanemab, aka N3pG, is a humanized IgG1 monoclonal antibody developed from mouse mE8-IgG2a. This biologic drug …
Leqembi - ALZFORUM
WEBOverview. Name: Leqembi Synonyms: Lecanemab-irmb, BAN2401, mAb158 Therapy Type: Immunotherapy (passive) Target Type: Amyloid-Related Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Approved) Company: BioArctic AB, Biogen, Eisai Co., Ltd. Background. BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble ...
Davos Alzheimer’s Consortium to Link Global Cohorts
WEBSep 24, 2021 — Christopher Rowe Austin Hospital; Posted: 24 Sep 2021 The fight against Alzheimer's disease and other dementias must be a global endeavor where research is strategic and efficient and advances are quickly shared between researchers and implemented into local communities.
AL002 - ALZFORUM
WEBNov 6, 2023 — Overview. Name: AL002 Therapy Type: Immunotherapy (passive) Target Type: Inflammation Condition(s): Alzheimer's Disease U.S. FDA Status: Alzheimer's Disease (Phase 2) Company: AbbVie, Alector Background. This humanized monoclonal IgG1 antibody is being developed in a partnership between Alector and AbbVie. It binds the microglial receptor TREM2 and activates signaling, increasing ...
Bepranemab - ALZFORUM
WEBJan 23, 2022 — Overview. Name: Bepranemab Synonyms: UCB0107 , UCB 0107 , Antibody D Therapy Type: Immunotherapy (passive) Target Type: Tau Condition(s): Progressive Supranuclear Palsy, Alzheimer's Disease U.S. FDA Status: Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) Company: Hoffmann-La Roche, UCB S.A. Background. This humanized, monoclonal IgG4 antibody binds to the central region ...
What Is Early Onset Familial Alzheimer Disease (eFAD)?
WEBEarly onset familial Alzheimer disease (eFAD) is hereditary and marked by Alzheimer disease symptoms that appear at an unusually early age. Symptoms can start in a person's thirties, forties, and fifties (and very rarely in the late twenties). Generally, if you are diagnosed with eFAD, then one of ...
Memantine—Good for a Year, But Little Disease Modification
WEBJan 16, 2018 — 12 Jan 2006. The drug memantine is a safe and effective therapy that helps patients suffering from moderate to severe Alzheimer disease for up to a year.